Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Research
Company announces publication that pinpoints TAP defect in metastatic carcinomas
September 14th, 2005
GeneMax Corp. (GMXX), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced that a scientific paper coauthored by the company's CSO, Dr. Wilfred Jefferies, and his research collaborators from the University of British Columbia, has been published in Cancer Research (August 15, 2005, vol. 65 no. 16), the journal of the American Association for Cancer Research. The paper, entitled "Identification of Mechanisms Underlying Transporter Associated with Antigen Processing (TAP) Deficiency in Metastatic Murine Carcinomas," describes several novel aspects of TAP deficiencies in...
Source: Vaccine Weekly (2005-09-14)
|
